PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
52.59
-0.21 (-0.40%)
Mar 7, 2025, 4:00 PM EST - Market closed
PTC Therapeutics Revenue
In the year 2024, PTC Therapeutics had annual revenue of $806.78M, down -13.97%. PTC Therapeutics had revenue of $213.17M in the quarter ending December 31, 2024, a decrease of -30.58%.
Revenue (ttm)
$806.78M
Revenue Growth
-13.97%
P/S Ratio
5.01
Revenue / Employee
$859,191
Employees
939
Market Cap
4.15B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 806.78M | -131.04M | -13.97% |
Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PTCT News
- 22 hours ago - PTC Therapeutics: Upside In Rare Disease Innovation - Seeking Alpha
- 10 days ago - PTC Therapeutics, Inc. (PTCT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 17 days ago - PTC Therapeutics to Participate in Upcoming Investor Conferences - PRNewsWire
- 18 days ago - PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia - PRNewsWire
- 24 days ago - PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 7 weeks ago - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 7 weeks ago - PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire